106 results about "Upper third" patented technology

The invention relates to a vehicle seat with a seat part and with a seat back part for supporting a driver of the vehicle in the sitting position on the vehicle seat, wherein the vehicle seat is characterized by an additional vehicle driver's torso support device which can be disposed outside the seat part and the seat back part and which can be temporarily disposed at least partially in an otherwise seat-free torso support region at the level of or above the upper third of the seat back part in front of the seat back part and laterally off-centre on the seat back part, in order to provide support, laterally off-centre of the seat back part, at least at the level of the shoulder or chest region of the driver who is sitting on the vehicle seat when he adopts a seated working posture oriented to the side or backwards, wherein the additional vehicle driver's torso support device is disposed so as to be movable by a moving device from a parked position into an additional torso support position in the otherwise seat-free torso support region.

Methods and compositions for preventing and treating the damaged and / or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and / or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.

Methods and pharmaceutical compositions for providing neuroprotection to the animal central nervous system against the effects of ischemia, and neurodegeneration. Patients at risk for certain diseases or disorders that are associated with cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators and copper chelators. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO provides an effective method for pre-conditioning the brain to protect against cerebral ischemia.

Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and / or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.

A balance (100) has a balance housing (200), a balance pan (300), a weighing compartment (310) that contains the balance pan, a draft shield (400) with a fixed rear wall (210), the draft shield enclosing the weighing compartment, a system of balance electronics (500), a weighing cell (600) arranged below the weighing pan, and a weighing cell compartment (270) that encases the weighing cell. The weighing cell compartment is atmospherically connected by way of a hollow space (240) to the upper third of the weighing compartment. The balance electronics are arranged at the rear wall outside of the weighing compartment.

A hood apparatus has structure to be removably engagable to a jacket and further structure to help eliminate reduced user peripheral vision from the hood via the user turning their head side to side. The structure of the hood is to create a slackened removable engagement between the hood and the jacket. Further structure of the hood is to provide multiple axes of adjustability for the hood to form around a user's head in effect causing the hood move in lockstep to the user's side to side head movement. These multiple axes of adjustability include a circumferential elastic drawstring positioned about the user's face periphery and an added independent lateral elastic drawstring that is partially parallel to the circumferential elastic drawstring for about an upper one-third of the user's face periphery wherein the lateral elastic drawstring is routed laterally toward the rear of the hood.

Evaporation of calciferous water is performed by an evaporator using electrical heating. An injection nozzle is connected to a spray hose arranged in an upper third of the evaporator, immediately above a thermostat that is disposed on the bottom side of the evaporator. A distance between the injection nozzle and the thermostat is less than 15 mm. A steam hose is connected to the evaporator via a steam connector. The steam connector has an inside diameter of at least 5 mm. The steam hose leads to a collector situated at an angle of inclination of 5° to 10°.